Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

Inclusion Criteria: * Age older than 18 years * Scheduled for elective or ad-hos PCI * Aspirin use daily for greater or equal to one week * Aspirin resistant (ARU greater than or equal to 550 on Verify Now-ASA Exclusion Criteria: * Pre-procedural elevation of cardiac biomarkers (CK-MB greater or equal to 10.4ng/dl or Tnl greater or equal to 0.4ng/dl * administration of any GP IIb/IIIa inhibitor, anticoagulation or lytic therapy in the previous 30 days * Ongoing bleeding or bleeding diathesis, contraindications for anticoagulation or increased bleeding risk or history of bleeding in the last eight weeks * Previous stroke or transient ischemic attack or any intracranial pathology in the last six months, major surgery or trauma within the previous six weeks * Platelet count less than hundred thousand per cubic millimeter or hematocrit \<33% or hemoglobin \<11 g per deciliter * Subjects who received full dose low molecular weight heparin within six hours prior to randomization * Allergy or intolerance to any of the study drugs or the presence of any serious comorbidity with life expectancy of ≤1year * Scheduled for saphenous vein graft intervention, chronic total occlusions or with impaired renal function (eGFR\<60ml/min) or patients who were taking anticoagulants or antiplatelet agents other than aspirin and clopidogrel or nonsteroidal anti-inflammatory drugs within two weeks before the PCI procedure